Investors sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading on Monday after an insider sold shares in the company. $66.06 million flowed into the stock on the tick-up and $110.85 million flowed out of the stock on the tick-down, for a money net flow of $44.79 million out of the stock. Of all companies tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.97 for the day and closed at $83.06Specifically, major shareholder Lilly Endowment Inc sold 240,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $82.87, for a total transaction of $19,888,800.00. Following the transaction, the insider now directly owns 126,020,570 shares in the company, valued at $10,443,324,635.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 1,213 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $83.16, for a total transaction of $100,873.08. Following the transaction, the insider now owns 1,300 shares in the company, valued at $108,108. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

LLY has been the topic of a number of research reports. Deutsche Bank AG restated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, September 20th. Jefferies Group restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research report on Wednesday, September 14th. Leerink Swann restated a “buy” rating and set a $103.00 target price on shares of Eli Lilly and in a research report on Sunday. Credit Suisse Group AG restated a “buy” rating and set a $91.00 target price on shares of Eli Lilly and in a research report on Wednesday, July 6th. Finally, Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Wednesday, October 5th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $97.06.

The stock has a market capitalization of $87.85 billion, a PE ratio of 35.80 and a beta of 0.17. The firm’s 50-day moving average is $79.55 and its 200 day moving average is $77.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The company earned $5.40 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter in the prior year, the business posted $0.90 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Co. will post $3.59 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Nadler Financial Group Inc. acquired a new position in Eli Lilly and during the third quarter valued at about $213,000. Bremer Trust National Association boosted its position in Eli Lilly and by 72.1% in the third quarter. Bremer Trust National Association now owns 6,046 shares of the company’s stock valued at $485,000 after buying an additional 2,532 shares during the last quarter. Triangle Securities Wealth Management acquired a new position in Eli Lilly and during the third quarter valued at about $894,000. Atalanta Sosnoff Capital LLC acquired a new position in Eli Lilly and during the third quarter valued at about $26,397,000. Finally, Indiana Trust & Investment Management CO boosted its position in Eli Lilly and by 1.5% in the third quarter. Indiana Trust & Investment Management CO now owns 10,815 shares of the company’s stock valued at $868,000 after buying an additional 155 shares during the last quarter. 74.96% of the stock is owned by institutional investors.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.